American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
-
Am J Health Syst Pharm · Dec 2017
Editorial Historical ArticleASHP at 75 Years: Celebrating the past and embracing the future.
-
Trends in shortages of vaccines and immune globulin products from 2001 through 2015 in the United States are described. ⋯ Drug shortages of vaccines and immune globulin products accounted for only 2.8% of reported drug shortages within a 15-year period, but about half of these shortages involved products on the pediatric vaccination schedule, which may have significant public health implications.
-
Am J Health Syst Pharm · Sep 2017
Using predictive analytics and big data to optimize pharmaceutical outcomes.
The steps involved, the resources needed, and the challenges associated with applying predictive analytics in healthcare are described, with a review of successful applications of predictive analytics in implementing population health management interventions that target medication-related patient outcomes. ⋯ Predictive analytics that leverage big data will become an indispensable tool for clinicians in mapping interventions and improving patient outcomes.
-
Am J Health Syst Pharm · Sep 2017
Effectiveness of interventions to improve medication use during rapid-sequence intubation in a pediatric emergency department.
Results of a study to determine whether checklist-based interventions improved the selection and administration of rapid-sequence intubation (RSI) medications in a pediatric emergency department (ED) are reported. ⋯ In a quality-improvement project in a pediatric ED, a checklist-based intervention improved RSI medication administration technique but not selection.
-
Am J Health Syst Pharm · Aug 2017
ReviewSelexipag for the treatment of pulmonary arterial hypertension.
The pharmacology, pharmacokinetics, clinical efficacy, safety and tolerability, dosing and administration, and place in therapy of selexipag, an orally administered selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension (PAH), are reviewed. ⋯ Selexipag is an oral prostacyclin IP receptor agonist approved for use as monotherapy or in combination with other therapies to slow PAH progression and reduce the risk of hospitalization in patients with FC II or III symptoms. Its stability and relatively long half-life offer conveniences over conventional prostanoid therapies.